For the quarter, we posted organic sales growth of 8.4% versus 2019, driven by excellent double-digit growth from our MedSurg and Neurotechnology businesses, but this was offset by softer sales of hip, knee and spine due to the resurgence of COVID-19.
International organic growth of 12%, again, outpaced growth in the US, representing robust performances and lessening impacts of COVID-19 across most major geographies, including strong results across Europe, Australia, Canada and emerging markets.
Our year-to-date organic growth is 7.6%.
And with the continued uncertainty related to COVID recovery as well as healthcare staffing shortages, we are updating our full year organic sales growth guidance to 7% to 8% compared to 2019.
Our adjusted earnings per share grew 15% versus 2019, and we continued our focus on driving cash flow, leading to a year-to-date cash conversion of 87%.
Including Wright Medical, the combined US Trauma and Extremities business has grown 8.1% year-to-date.
Outside the United States, sales have declined 3.8% year-to-date, driven by timing of distributor conversions in Latin America and Asia Pacific and declines in our legacy Trauson and Trauma business in China as a result of the provincial tendering process.
Our organic sales growth was 8.4% in the quarter.
Compared to 2019, the two year impact from pricing in the quarter was unfavorable 2.2%.
Versus Q3 2020, pricing was 0.7% unfavorable.
Foreign currency had a favorable 1.2% impact on sales.
For the quarter, US organic sales increased 7.1%, reflecting the continued strong demand for Mako, instruments, medical and neurovascular products.
International organic sales showed strong growth of 12%, impacted by positive sales momentum in Europe, Australia, Canada and emerging markets.
Our adjusted quarterly earnings per share of $2.20 increased 15.2% from 2019, reflecting sales growth, gross margin expansion and a lower quarterly effective tax rate, partially offset by the impact of business mix and higher interest charges resulting from the Wright acquisition.
Our third quarter earnings per share was positively impacted from foreign currency by $0.04.
Orthopaedics had constant currency sales growth of 19.9% and organic sales growth of 2%, including organic growth of 1% in the US.
Our knee business grew 0.9% organically in the US, reflecting the previously mentioned impact on elective procedures, offset by continued adoption of our robotic platform for total knee procedures.
Our US trauma business grew 8.8%, reflecting solid performances across the portfolio.
Other ortho grew 19.8% in the US, primarily reflecting demand for our Mako robotic platform, partially offset by declines in bone cement.
Internationally, Orthopaedics grew 4.1% organically, which reflects the strong performances in Europe and the momentum in Mako internationally, somewhat offset by the increased impact of restrictions imposed on elective procedures due to COVID, especially in Japan.
For the quarter, our Trauma and Extremities business, which includes Writer Medical delivered 3.2% growth on a comparable basis.
In the US, comparable growth was 7.4%, which included double digital growth in our upper extremities business.
In the quarter, MedSurg had constant currency and organic sales growth of 12%,,which included 12% US organic growth as well.
Instruments had US organic sales growth of 15.9%, led by double digit growth in their orthopedic implants and surgical technology businesses, which include power tools, waste management, smoke evacuation and skin closure products.
Endoscopy had US organic sales growth of 10.6%, reflecting strong performances across their portfolio, including video and general surgery products and strong double digit growth of their communications and sports medicine businesses.
The Medical division had US organic growth of 12.5%, reflecting double-digit performances in its emergency care and Sage businesses.
Internationally, MedSurg had organic sales growth of 12%, reflecting strong growth in the Endoscopy, Instruments and Medical businesses across Europe and Australia.
Neurotechnology and Spine had organic growth of 11.8%.
Our Neurovascular business had particularly strong growth of approximately 26% and makes up roughly 30% of this segment.
Our US Neurotech business posted an organic growth of 11.8%, reflecting strong product growth in Sonopet iQ, Bipolar Forceps and Bone Mill.
Internationally, Neurotechnology and Spine had organic growth of 24.6%.
Our adjusted gross margin of 66.3% was favorable approximately 55 basis points from third quarter 2019.
Adjusted R&D spending was 6.7% of sales, reflecting our continued focus on innovation.
Our SG&A was 34.1% of sales, which was slightly negative as compared to the third quarter of 2019.
In summary, for the quarter, our adjusted operating margin was 25.4% of sales, which is approximately the same as third quarter 2019.
Our third quarter had an adjusted effective tax rate of 14%, which was impacted by our mix of US, non-US income and favorable discrete items during the quarter.
Our year-to-date effective tax rate is 14.8%.
For the year, we continue to expect an adjusted effective tax rate of 15% to 15.5%.
Focusing on the balance sheet, we ended the third quarter with $2.6 billion of cash and marketable securities and total debt of $12.7 billion.
year-to-date, we have paid down $1.2 billion of debt.
In October, we completed the refinancing of our revolving credit facility and increased that facility from $1.5 billion to $2.25 billion.
Our year-to-date cash from operations was approximately $2.3 billion.
Based on our performance in the third quarter, the continued volatility experienced as a result of COVID, procedural delays in hospital staffing shortages as well as uncertainty around the pace of recovery in the fourth quarter, we expect 2021 organic net sales growth to be in the range of 7% to 8%.
If foreign currency exchange rates hold near current levels, we expect net sales in the full year will be positively impacted by approximately 1%.
Adjusted net earnings per diluted share will be positively impacted by approximately $0.05 to $0.10 in the full year and this is included in our revised guidance range.
Based on our performance in the first nine months and including consideration of the aforementioned volatility impacting the recovery of elective procedures and the full year Wright Medical impact, we now expect adjusted net earnings per diluted share to be in the range of $9.08 to $9.15.
